Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00976235
Other study ID # IMT-002-LTM
Secondary ID
Status Completed
Phase N/A
First received September 10, 2009
Last updated November 1, 2017
Start date June 2006
Est. completion date May 2011

Study information

Verified date November 2017
Source VisionCare, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 5-year study of patients implanted with the Implantable Miniature Telescope (IMT by Dr. Isaac Lipshitz) under Protocol IMT-002. All patients implanted with the telescope prosthesis who enrolled in the IMT-002 trial were asked to participate in this study to monitor long-term safety. Patients will undergo examinations at six-month intervals up to a total of 5 years following implantation.


Description:

Every 6 months, manifest refraction, visual acuity, intraocular pressure, slit lamp examination, endothelial cell density, device failures, complications and adverse events will be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 129
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender All
Age group 55 Years and older
Eligibility Inclusion Criteria:

- Patients must have participated in the IMT-002 trial.

- Patients must be able to understand and comply with the requirements of the clinical study, and be able to abide by the requirements and restrictions of the study.

- Patients must be able to provide voluntary informed consent, and must sign and be given a copy of the written Informed Consent form.

Exclusion Criteria:

- Patients who have not participated in the IMT-002 trial.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
IMT - Implantable Miniature Telescope
Implantation of the telescope prosthesis (performed under the initial study)

Locations

Country Name City State
United States W.K. Kellogg Eye Center Ann Arbor Michigan
United States Emory Eye Center Atlanta Georgia
United States Wilmer Ophthalmological Institute Baltimore Maryland
United States Retina Associates of Cleveland Beachwood Ohio
United States Massachusetts Eye & Ear Infirmary Boston Massachusetts
United States Ophthalmic Consultants of Boston Boston Massachusetts
United States Southeast Clinical Research Charlotte North Carolina
United States Retina Group of Washington Chevy Chase Maryland
United States Kraft Eye Institute Chicago Illinois
United States Duke University Eye Center Durham North Carolina
United States Fine, Hoffman & Packer Eugene Oregon
United States Baylor College of Medicine Houston Texas
United States Discover Vision Centers Independence Missouri
United States University of California at Irvine Irvine California
United States Altos Eye Physician Los Altos California
United States Doheny Retina Institute - University of Southern California Los Angeles California
United States Vitreoretinal Foundation Memphis Tennessee
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Vanderbilt University Nashville Tennessee
United States Manhattan Eye & Ear New York New York
United States Dean A. McGee Eye Institute Oklahoma City Oklahoma
United States Paducah Retinal Center Paducah Kentucky
United States Wills Eye Hospital Philadelphia Pennsylvania
United States Associated Retinal Consultants Royal Oak Michigan
United States Medical Center Ophthalmology San Antonio Texas
United States Sarasota Retinal Institute Sarasota Florida
United States Associated Eye Care Stillwater Minnesota
United States Retina Centers P.C. Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
VisionCare, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Long term safety (Intraocular pressure, Slit lamp, Endothelial Cell Density, Visual Acuity, Complications, Adverse Events and Device Failures) 5 years from implantation
See also
  Status Clinical Trial Phase
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Completed NCT02540954 - Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Phase 3
Completed NCT00385333 - Metabolic Mapping to Measure Retinal Metabolism Phase 2
Completed NCT02510794 - Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration Phase 2
Completed NCT02181504 - A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration Phase 2
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Terminated NCT02228304 - Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT01204541 - A Single-Center Pilot Study to Assess Macular Function N/A
Completed NCT00769392 - Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection N/A
Completed NCT00533520 - Evaluation of Dosing Interval of Higher Doses of Ranibizumab Phase 4
Withdrawn NCT00538538 - Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) Phase 1
Completed NCT00536016 - A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD Phase 1
Terminated NCT00403442 - Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD Phase 1
Recruiting NCT00157976 - Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration Phase 3
Completed NCT00242580 - A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Phase 3
Completed NCT00211458 - Treatment of Age-Related Macular Degeneration With Anecortave Acetate Phase 2
Completed NCT00239928 - Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration Phase 2
Completed NCT00095433 - Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) Phase 3
Completed NCT00006202 - Lutein for Age-Related Macular Degeneration Phase 2